LTLuis-Esteban Tamariz-Amador

Luis-Esteban Tamariz-Amador

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luis-Esteban Tamariz-Amador has a total of 287 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Minimal Residual Disease (MRD) in Multiple Myeloma: From Prognostic Marker to Therapeutic Compass

    by Luis-Esteban Tamariz-Amador, Paula Rodriguez-Otero, Andrea Manubens, Marta Lasa, Carmen Gonzalez, Bruno Paiva, Jesús San-Miguel

    Multiple myeloma has long been considered incurable; however, advances in therapy have markedly improved outcomes, with a growing proportion of patients achieving sustained remissions suggestive of cure. Minimal (or measurable) residual disease (MRD) has emerged as the most informative biomarker for assessing depth of response and predicting clinical outcomes. Evidence consistently demonstrates that MRD negativity surpasses conventional complete response in prognostic value across disease settings, treatment regimens, and risk groups. Furthermore, MRD has shown potential as a surrogate endpoint for clinical trials and as a tool to guide therapeutic decisions, including treatment intensification, de-escalation, and maintenance strategies. Emerging data also support its relevance in the context of immunotherapy and non–bone marrow-based assessment approaches. Collectively, these findings position MRD as a central component in the evolution toward more precise and individualized management of multiple myeloma.

  • Open Access

    Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response

    by Itziar Cenzano, Miguel CócEra, Marta Larrayoz, Lorea Campos-Dopazo, Sonia Sanz, Azari Bantan, Amaia Vilas-Zornoza, Patxi San-Martin, Paula Aguirre-Ruiz, Diego Alignani, et al.

    Progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is accompanied by profound remodeling of the bone marrow microenvironment (BME), yet the contribution of its non-immune compartment remains unclear. Using single-cell RNA sequencing in genetically engineered mouse models that recapitulate disease evolution, we transcriptionally profile endothelial cells (EC) and mesenchymal stem cells (MSC). EC adopt a stress-associated program at MGUS that precedes angiogenesis in MM, while MSC undergo early and sustained loss of differentiation capacity. We identify a coordinated interferon (IFN)-driven program across EC and MSC that defines MM in the BIcγ1 model but is absent in the more aggressive MI cγ1 model. Treatment with bortezomib, lenalidomide, and dexamethasone suppresses this IFN signature, promotes endothelial adaptation, and restores osteogenic potential in MSC. Validation in patient samples reveals enrichment of this IFN-signature across disease stages. These findings define dynamic and targetable alterations in the non-immune BME during myeloma progression.


  • Top Cited Papers
    Open Access

    Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs

    by Tomas Jelinek, David Zihala, Aintzane Zabaleta, Ioannis V. Kostopoulos, Ondrej Soucek, Ondrej Venglar, Cristina Moreno, Despina Fotiou, Eva Radova, Luis Esteban Tamariz-Amador, et al.

    Infections remain a challenge during treatment of patients with multiple myeloma (MM) with anti–B-cell maturation antigen (BCMA) and anti–G protein-coupled receptor class C group 5 member D (GPRC5D) bispecific antibodies (bsAbs). However, the mechanism underlying different rates and severity of infections induced by the 2 bsAbs remains poorly understood. Single-cell RNA sequencing of bone marrow (BM) aspirates of 11 patients with MM and 8 healthy donors revealed BCMA expression on mature B cells and, surprisingly, in small pre-B cells within B-cell precursors. GPRC5D expression was restricted to malignant and less to normal plasma cells (PCs). Next-generation flow cytometry immune profiling showed that anti-BCMA bsAbs severely depleted BM mature B cells, from 4.9% to 0% (P< .001), and normal PCs, from 0.17% to <0.0002% (P< .001), during treatment of 62 patients with relapsed MM. This was observed throughout therapy. Additional flow cytometry (n = 31) and single-cell RNA sequencing studies (n = 8) demonstrated that, in contrast to anti-GPRC5D, anti-BCMA bsAbs also depleted immature and small pre-B cells. The MIcγ1 mouse model was used as a negative control of BCMA expression in all stages of the B-cell lineage, confirming no depletion of any B-cell subset after anti-BCMA treatment. In conclusion, we show that although GPRC5D bsAbs selectively target PCs, anti-BCMA bsAbs target both PCs and B cells from the small pre-B stage onward. Our study provides mechanistic insight into the increased infection risk with anti-BCMA therapy and supports individualized bsAb strategies in MM. Moreover, dual targeting of B cells and PCs may have therapeutic potential in other B-cell malignancies or autoimmune diseases.


  • Open Access

    Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myeloma

    by Lorea Jordana-Urriza, Guillermo Serrano, Sergio Camara-Peña, Maria E. Calleja-Cervantes, Patxi San Martin-Uriz, Aintzane Zabaleta, Aina Oliver-Caldes, Marta Español-Rego, Diego Alignani, Teresa Lozano, et al.


  • Immune biomarkers of increased infection risk in multiple myeloma

    by Aintzane Zabaleta, Luis-Esteban Tamariz-Amador, Ioannis V Kostopoulos, Romanos Sklavenitis Pistofidis, Febe Smits, Paula Rodriguez-Otero, Carmen Roncal, Michelle P Aranha, David Žihala, Michaela Machu, et al.

    Infection remains a leading cause of morbidity in multiple myeloma. Preventing infections is paramount and immune profiling could reflect the cumulative effect of host, tumor and treatment-related immunosuppression. However, current understanding of immune dysfunction and its association with infection is limited. To address this gap in knowledge and identify immune biomarkers of increased infection risk, we performed immune profiling using next-generation flow cytometry in bone marrow and peripheral blood samples from 1,786 patients at various disease stages and treatment scenarios. Patients developing infection had significantly lower percentages of CD27+ B cells and CD27- NK cells, as well as increased CD27-/CD27+ T-cell ratio in bone marrow. These immune risk factors were validated in three independent datasets. An immune score was developed to stratify patients with ≤1 vs ≥2 of the aforementioned risk factors, which was associated with higher infection incidence (35% vs 60%, P <.001). The immune score (odds ratio: 2.31, P <.001), disease stage and CD38, BCMA or GPRC5D targeted therapy were independently associated with infection incidence. All cell types detectable in bone marrow and peripheral blood were significantly correlated, suggesting that immune biomarkers of increased infection risk could be monitored using minimally-invasive methods that are available in routine laboratories.


  • Open Access

    Emerging Risk of Campylobacter spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies

    by Idoia Bilbao, María Ansón, Sara Villar, Iñigo Pineda, Laura Gárriz, Manuel Pina-Sánchez, Luis-Esteban Tamariz-Amador, Paula Rodríguez-Otero, José Ramón Yuste, José L del Pozo

    Bispecific antibodies directed against BCMA and GPRC5D have shown remarkable efficacy in patients with refractory multiple myeloma; however, concerns regarding infection risk are emerging. In a cohort of 85 treated patients, we observed a notable incidence of Campylobacter infections, including 5 bloodstream and 5 gastrointestinal episodes, affecting 9 individuals. This unexpectedly high burden of infection highlights the vulnerability of this immunocompromised population and underscores the urgent need for studies evaluating targeted preventive and surveillance strategies.


  • Open Access

    Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T‐cell redirecting immunotherapy

    by Aintzane Zabaleta, Noemi Puig, Maria‐Teresa Cedena, Aina Oliver‐Caldes, José J. Perez, Cristina Moreno, Luis‐Esteban Tamariz‐Amador, Paula Rodriguez‐Otero, Felipe Prosper, Veronica Gonzalez‐Calle, et al.

    The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma (RRMM) patients treated with T‐cell redirecting immunotherapy is uncertain. We analyzed MRD dynamics using next‐generation flow in 201 patients treated in clinical trials with chimeric antigen receptor (CAR) T cells and T‐cell engagers (TCE). Achieving MRD negativity at 10 −6 was associated with 89% reduction in the risk of progression and/or death. Survival outcomes were improved in patients with sustained versus transient MRD negativity and were dismal in those who remained MRD positive. The intent‐to‐treat MRD negative rates were higher in patients treated with CAR T cells versus TCE. However, among patients achieving MRD negativity, there were no differences in survival outcomes when stratified according to treatment with CAR T cells versus TCE. In multivariate analysis including the number of prior lines of treatment, International Staging System, cytogenetic risk, extramedullary disease and type of T‐cell redirecting immunotherapy, only the complete remission (CR) and MRD statuses showed independent prognostic value for progression‐free and overall survival. In conclusion, our study shows that deep and sustained MRD negative CR is the most relevant prognostic factor and should be considered as the treatment endpoint in RRMM patients treated with CAR T cells and TCE.


  • Open Access

    Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma

    by Maria Luisa Palacios-Berraquero, Paula Rodriguez-Marquez, Maria Erendira Calleja-Cervantes, Nerea Berastegui, Aintzane Zabaleta, Leire Burgos, Diego Alignani, Patxi San Martin-Uriz, Amaia Vilas-Zornoza, Saray Rodriguez-Diaz, et al.

    Hematologic toxicity is a common side effect of chimeric antigen receptor T-cell (CAR-T) therapies, being particularly severe among patients with relapsed or refractory multiple myeloma (MM). In this study, we characterized 48 patients treated with B-cell maturation antigen (BCMA) CAR-T cells to understand kinetics of cytopenia, identify predictive factors, and determine potential mechanisms underlying these toxicities. We observed that overall incidence of cytopenia was 95.7%, and grade >3 thrombocytopenia and neutropenia, 1 month after infusion, was observed in 57% and 53% of the patients, respectively, being still present after 1 year in 4 and 3 patients, respectively. Baseline cytopenia and high peak inflammatory markers were highly correlated with cytopenia that persisted up to 3 months. To determine potential mechanisms underlying cytopenias, we evaluated the paracrine effect of BCMA CAR-T cells on hematopoietic stem and progenitor cell (HSPC) differentiation using an ex vivo myeloid differentiation model. Phenotypic analysis showed that supernatants from activated CAR-T cells (spCAR) halted HSPC differentiation, promoting more immature phenotypes, which could be prevented with a combination of interferon γ, tumor necrosis factor α/β, transforming growth factor β, interleukin-6 (IL-6) and IL-17 inhibitors. Single-cell RNA sequencing demonstrated upregulation of transcription factors associated with early stages of hematopoietic differentiation in the presence of spCAR (GATA2, RUNX1, CEBPA) and a decrease in the activity of key regulons involved in neutrophil and monocytic maturation (ID2 and MAFB). These results suggest that CAR-T activation induces HSPC maturation arrest through paracrine effects and provides potential treatments to mitigate the severity of this toxicity.


  • A CD38 / CD3xCD28 trispecific T‐cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti‐ CD38 monoclonal antibodies

    by Aintzane Zabaleta, Laura Blanco, Peter S. Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Marta Lasa, Luis‐Esteban Tamariz‐Amador, Paula Rodriguez‐Otero, Jesús San‐Miguel, et al.

    Summary: There is accumulating evidence of BCMA and GPRC5D loss after treatment with T‐cell redirecting therapies in patients with relapsed/refractory multiple myeloma (RRMM). While complete CD38 loss is not observed upon relapses after treatment with anti‐CD38 monoclonal antibodies (mAb), there is downregulation of surface CD38 expression and decreased number and function of NK cells, which renders these patients resistant to retreatment with anti‐CD38 mAb. Here, we provide preclinical evidence that RRMM patients previously exposed to anti‐CD38 mAb could benefit from T‐cell‐based immunotherapy that depend less on CD38 antigen density and NK‐cell activity, such as the novel CD38/CD3xCD28 trispecific T‐cell engager, SAR442257.


  • Open Access

    Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    by Esperanza Martín-Sánchez, Luis-Esteban Tamariz-Amador, Camila Guerrero, Anastasiia Zherniakova, Aintzane Zabaleta, Catarina Maia, Laura Blanco, Diego Alignani, Maria-Antonia Fortuño, Carlos Grande, et al.

    Infection is the leading cause of death in multiple myeloma (MM). However, the cellular composition associated with immune dysfunction is not defined. We analyzed immune profiles in the peripheral blood of patients with MM (n = 28) and B-cell chronic lymphoproliferative disorders (n = 53) vs. health care practitioners (n = 96), using multidimensional and computational flow cytometry. MM patients displayed altered distribution of most cell types (41/56, 73%), particularly within the B-cell (17/17) and T-cell (20/30) compartments. Using COVID-19 as a case study, we compared the immune response to vaccination based on 64,304 data points generated from the analysis of 1099 longitudinal samples. MM patients showed limited B-cell expansion linked to lower anti-RBD and anti-S antibody titers after the first two doses and booster. The percentages of B cells and CD4+ T cells in the blood, as well as the absolute counts of B cells and dendritic cells, predicted vaccine immunogenicity at different time points. In contrast with the humoral response, the percentage and antigen-dependent differentiation of SARS-CoV-2-specific CD8+ T cells was not altered in MM patients. Taken together, this study defined the cellular composition associated with immune dysfunction in MM and provided biomarkers such as the B-cell percentage and absolute count to individualize vaccination calendars.